Spinal Metastases Clinical Trial
Official title:
A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy(SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Patients With Spinal Metastases
NCT number | NCT02512965 |
Other study ID # | SC24 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 4, 2016 |
Est. completion date | August 16, 2021 |
Verified date | August 2021 |
Source | Canadian Cancer Trials Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to find out if SBRT is better than CRT at controlling pain in the spine 3 months after receiving treatment.
Status | Completed |
Enrollment | 229 |
Est. completion date | August 16, 2021 |
Est. primary completion date | July 21, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologic or cytologic diagnosis of cancer (excluding seminoma, small cell lung cancer and hematologic primaries). - Spinal metastasis documented with MRI and suitable for treatment with radiotherapy with the following characteristics: - Painful, as defined by a pain score = 2 for worst pain in the planned target treatment volume; - = 3 consecutive spinal segments involved by tumour to be included in the planned target volume. The patient may have other spinal metaastases to be treated as per the radiation oncologist's discretion, but the eligible spinal metastatic site has to be one where there is pain and no more than 3 consecutive segments to be included as clinical target volume and appropriate for either 20 Gy in 5 fractions or 24 Gy in 2 fractions per the randomization. - There is no plan to change the pain medication on the first day of protocol treatment with radiotherapy. - ECOG Performance Status 0-2. - Seen by a radiation oncologist and judged to be appropriate for participation in this study including ability to tolerate protocol radiotherapy (SBRT or CRT). - Age of 18 years or older. - Patient is able and willing to complete the Patient Diary (pain and analgesic use). - Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaire in either English or French. The baseline assessment must be completed within required timelines, prior to randomization. Inability (illiteracy in English or French, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible. - Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate. - Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up. - In accordance with CCTG policy, protocol treatment is to begin within 3 weeks of patient randomization. From the time of successful treatment planning, no more than 12 days can elapse before the first fraction of radiotherapy is delivered. - Women/men of childbearing potential must have agreed to use a highly effective contraceptive method. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures. - Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected. For example, when beta-human chorionic gonadotropin is high and partner is vasectomized, it may be associated with tumour production of hCG, as seen with some cancers. Patient will be considered eligible if an ultrasound is negative for pregnancy. Exclusion Criteria: - Patients who have a pacemaker, such that MRI cannot be performed or treatment cannot be delivered safely. - Patients with prior treatment with any radionuclide within 30 days prior to randomization. - Patients with prior radiation to the spinal segment intended to be treated with protocol radiotherapy such that the protocol therapy cannot be delivered as intended. - Patients with prior surgery to the spinal segment intended to be treated with protocol radiotherapy. - Patients who have received chemotherapy within 1 week prior to administration of protocol radiotherapy or who are expected/planned to receive chemotherapy within one week of completing protocol radiotherapy. Centre guidelines regarding administration of targeted non-cytotoxic therapy must be followed with the proviso that no systemic anticancer therapy should be administered within 24 hours prior to and post-radiotherapy. Endocrine therapy may be administered during radiotherapy as per the discretion of the treating physician. - Patients with spine instability as judged by a Spinal Instability Neoplastic Score (SINS) of more than 12. - Patients with symptomatic spinal cord compression or cauda equina syndrome resulting from bony compression or epidural compression of the spinal cord and cauda equina, respectively. Symptomatic refers to neurolic deficit in the form of motor, bowel or bladder dysfunction. - Pregnant or lactating women. |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Adelaide Hospital | Adelaide | South Australia |
Australia | Princess Alexandra Hospital | Brisbane | Queensland |
Australia | Canberra Hospital | Garran | |
Australia | Auckland City Hospital | Grafton | Aucklund |
Australia | Royal Brisbane and Womens Hospital | Herston | |
Australia | Liverpool Cancer Therapy Centre, Liverpool Hospital | Liverpool | New South Wales |
Australia | Peter McCallum Cancer Institute | Melbourne | Victoria |
Australia | Peter Mac - Sunshine Hospital | St Albans | Victoria |
Canada | Tom Baker Cancer Centre | Calgary | Alberta |
Canada | Cross Cancer Institute | Edmonton | Alberta |
Canada | Juravinski Cancer Centre at Hamilton Health Sciences | Hamilton | Ontario |
Canada | London Regional Cancer Program | London | Ontario |
Canada | CHUM-Centre Hospitalier de l'Universite de Montreal | Montreal | Quebec |
Canada | Ottawa Hospital Research Institute | Ottawa | Ontario |
Canada | BCCA - Centre for the North | Prince George | British Columbia |
Canada | CHUQ-Pavillon Hotel-Dieu de Quebec | Quebec City | Quebec |
Canada | Centre hospitalier universitaire de Sherbrooke | Sherbrooke | Quebec |
Canada | Odette Cancer Centre | Toronto | Ontario |
Canada | University Health Network | Toronto | Ontario |
Canada | BCCA - Vancouver Cancer Centre | Vancouver | British Columbia |
Canada | BCCA - Vancouver Island Cancer Centre | Victoria | British Columbia |
Canada | CancerCare Manitoba | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
Canadian Cancer Trials Group | Trans Tasman Radiation Oncology Group |
Australia, Canada,
Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, Butler J, Chow E, Fehlings MG, Foote M, Gabos Z, Greenspoon J, Kerba M, Lee Y, Liu M, Liu SK, Thibault I, Wong RK, Hum M, Ding K, Parulekar WR; trial investigators. Stereotactic body radi — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase III: Complete Pain Response at 3 Months Post-radiation | A Complete Pain Response is defined as a pain score of zero (0) at the treated site with no concomitant increase in analgesic intake (stable or reducing analgesics in daily oral morphine equivalent) . | 3 months | |
Secondary | Complete Pain Response at 6 Months Post Radiation Based on the International Bone Metastases Consensus Working Party Criteria | A Complete Pain Response is defined as a pain score of zero (0) at the treated site with no concomitant increase in analgesic intake (stable or reducing analgesics in daily oral morphine equivalent) . | 6 months post radiation | |
Secondary | Radiation Site Progression-free Survival Rate at 6 Months Using MRI Imaging | Radiation site progression was defined as:
Gross unequivocal increase in tumor volume or linear dimension > 20%. Any new or progressive tumor within the epidural space. Neurologic deterioration attributable to pre-existing epidural disease with equivocal increased epidural disease dimensions on MRI. |
6 months. | |
Secondary | Overall Survival Rate at 6 Months | Proportion of participants who were alive at 6 months in study. | 6 months post radiation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
Terminated |
NCT00593320 -
Stereotactic Radiosurgery (SRS) for Spine Metastases
|
N/A | |
Recruiting |
NCT05575323 -
Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases
|
N/A | |
Completed |
NCT02987153 -
Kypho-Intra Operative Radiation Therapy (IORT) for Localized Spine Metastasis, Phase I/II Study
|
N/A | |
Recruiting |
NCT03363685 -
Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis
|
||
Terminated |
NCT02407795 -
Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases
|
N/A | |
Completed |
NCT01365715 -
Preoperative Embolization in Surgical Treatment of Spinal Metastases.
|
N/A | |
Recruiting |
NCT04863612 -
SBRT in the Management of Solid Spinal Metastases
|
||
Recruiting |
NCT04242589 -
Trial of Combined Radiotherapy and Vertebroplasty for Patients With Painful Metastatic Spinal Lesions
|
Phase 2 | |
Recruiting |
NCT01849510 -
Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost
|
Phase 2 | |
Not yet recruiting |
NCT06244264 -
The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis
|
N/A | |
Not yet recruiting |
NCT06220071 -
Multicentric European Study In Patients With Vertebral Metastases
|
||
Completed |
NCT01290562 -
Stereotactic Body Radiotherapy (SBRT) for Spinal/Para-Spinal Metastases (Spine SBRT)
|
Phase 2 | |
Recruiting |
NCT06120426 -
En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.
|
||
Completed |
NCT03224650 -
Validation of Novel Predictive Score for Patients With Spinal Metastases
|
||
Not yet recruiting |
NCT06093854 -
Intraoperative Radiotherapy in Treating Spinal Metastases
|
N/A | |
Completed |
NCT02364115 -
Randomized Trial Comparing Conventional Radiotherapy With Stereotactic Radiotherapy in Patients With Bone Metastases - VERTICAL Study
|
N/A | |
Recruiting |
NCT03398915 -
The European Robotic Spinal Instrumentation (EUROSPIN) Study
|
||
Not yet recruiting |
NCT05173467 -
Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor
|
N/A | |
Recruiting |
NCT04248543 -
Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases
|
N/A |